SynAging Expands its Capabilities: Building a New Animal Facility and Hiring a Head of Pharmacology

SynAging, a world leading contract research organization (CRO) in the field of proteopathic neurodegenerative diseases such as Alzheimer’s and Parkinson’s, today announced the finalization and validation of its new animal facilities, significantly extending its capabilities for in vivo testing. In line with this, the company has expanded its team through the recruitment of additional skilled technical staff and hired Dr Pascal Goetghebeur as Head of Pharmacology.

SynAging plans to utilize its unique insights into protein biochemistry and folding as well as in vitro and in vivo models to support drug discovery and development for devastating neurodegenerative diseases. An extension of the company’s strategy of risk sharing collaborations in drug discovery is planned for the coming years.

SynAging is a spin-off from Lorraine University in Nancy, in the north of France. The company was founded in February 2010 by Violette Koziel (now President) and Dr. Thierry Pillot (now CEO and CSO) and occupies new labs on the university campus. SynAging management emphasized: ’We are extremely grateful for the support of Lorraine University in furthering our initial company development efforts, giving us access to crucial facilities and providing space for our expanding endeavors’. SynAging’s services have been designed to meet the needs of pharma and biotech companies, as well as the food and nutraceutical industry.

The company has gained an excellent reputation for time- and cost-effective service provision by producing robust data and providing new insights for neurodegenerative drug discovery. Andreas Köpke, external CBO of SynAging, remarked: ‘The SynAging team has worked efficiently to provide excellent and timely services to our international clients. The whole management team is very grateful to our staff for their enthusiasm and dedication”. The number of clients in international pharma and biotech companies has grown significantly over the last two years and the ever increasing revenue stream has enabled this cost effective company to extend its team and facilities without any external investments.

About SynAging: SynAging focuses on disease-inducing protein aggregates, which are involved in the earliest stages of proteopathic neurodegenerative diseases, like Alzheimer’s disease and Parkinson’s disease. As a French CRO located in Nancy, SynAging provides highly reproducible drug testing services, employing these proprietary protein aggregates to initiate disease symptoms in vitro and in vivo.

For further information:

SynAging SAS
Dr. Andreas Köpke, CBO
Phone: +49 6136 957 3000
E-mail: andreas.kopke@synaging.com
www.synaging.com